Literature DB >> 3973651

A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy.

T A Rich, J J Lokich, J T Chaffey.   

Abstract

A method to potentially increase the effectiveness of combination 5-fluorouracil (5-FU) and radiation therapy (XRT) using protracted (more than 30 days) venous infusion (PVI) of 5-FU with conventionally fractionated XRT (180 to 200 cGy per day) (100 cGy = 100 rad) is described. Forty-one patients were treated with this combination with acceptable acute toxicity. In 95% of patients, the toxicity was mild or moderate and symptom control was achieved with medications or a short treatment interruption. In two patients (5%), severe gastrointestinal side effects resulted in cessation of all therapy. This method of administration of 5-FU is feasible, and we have demonstrated that it can be safely used with a course of conventionally fractionated, high-dose (approximately to 6,500 cGy) radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973651     DOI: 10.1200/JCO.1985.3.3.402

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Suppository delivery of 5-fluorouracil in rectal cancer.

Authors:  S Galandiuk; W Wrightson; L Marr; S Myers; R V LaRocca
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

Review 2.  Adjuvant therapy for adenocarcinoma of the rectum.

Authors:  M J O'Connell; L L Gunderson
Journal:  World J Surg       Date:  1992 May-Jun       Impact factor: 3.352

Review 3.  Preoperative combined modality therapy for pancreatic cancer.

Authors:  T A Rich; D B Evans
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  N Martínez-Lago; M Vieito-Villar; Y Vidal-Insua; M E Padin-Iruegas; F Vazquez-Rivera; S Candamio-Folgar; R Lopez-Lopez
Journal:  Clin Transl Oncol       Date:  2015-07-02       Impact factor: 3.405

Review 5.  Combined modality therapy for esophageal cancer.

Authors:  Z Gamliel; M J Krasna
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 6.  Gemcitabine and radiosensitization in human tumor cells.

Authors:  D S Shewach; T S Lawrence
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.

Authors:  Shuo-Han Zheng; Song-Ran Liu; Hai-Bo Wang; Ying-Hong Wei; He Li; Guan-Nan Wang; Zi-Lu Huang; Shi-Rong Ding; Chen Chen; Ya-Lan Tao; Xiao-Hui Li; Christophe Glorieux; Peng Huang; Yang-Feng Wu; Yun-Fei Xia
Journal:  JAMA Netw Open       Date:  2021-12-01

8.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.